

PCT

WORLD INTELLECTUAL  
Internatio

WO 9603415A1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C07H 21/00, 21/04, C07K 14/435, 16/18, C12N 1/19, 1/21, 5/10, 15/12, 15/63, C12P 21/02</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 96/03415</b> (43) International Publication Date: 8 February 1996 (08.02.96)</p>
<p>(21) International Application Number: PCT/US94/08449 (22) International Filing Date: 28 July 1994 (28.07.94) (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; Suite 300, 9620 Medical Center Drive, Rockville, MD 20850-3338 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LI, Yi [CN/US]; 16125 Howard Landing Drive, Gaithersburg, MD 20878 (US). ADAMS, Mark, D. [US/US]; 15205 Dufief Drive, North Potamac, MD 20878 (US). WHITE, Owen, R. [US/US]; 886 Quince Orchard Boulevard #202, Gaithersburg, MD 20878 (US). (74) Agents: OLSTEIN, Elliot, M., et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart &amp; Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).</p>		<p>(81) Designated States: AU, CA, CN, JP, KR, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published With international search report.</p>
<p>(54) Title: HUMAN POTASSIUM CHANNEL 1 AND 2 PROTEINS (57) Abstract Disclosed are human K<sup>+</sup> channel polypeptides and DNA (RNA) encoding such K<sup>+</sup> channel polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques. Agonists for such K<sup>+</sup> channel polypeptides are also disclosed. Such agonists may be used to treat epilepsy, stroke, hypertension, asthma, Parkinson's disease, schizophrenia, anxiety, depression and neurodegeneration. Also disclosed are antagonists against such polypeptides which may be used to treat AIDS, SLE, diabetes, multiple sclerosis and cancer.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

### HUMAN POTASSIUM CHANNEL 1 AND 2 PROTEINS

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are human potassium channel proteins sometimes hereinafter referred to as a "K<sup>+</sup> channel 1 and 2 polypeptides." The invention also relates to inhibiting the action of such polypeptides.

Potassium channels probably form the most diverse group of ion channels, and are essential to the control of the excitability of nerve and muscle. Some potassium channels open in response to a depolarization of the membrane, others to a hyperpolarization or an increase in intracellular calcium. Some can also be regulated by the binding of a transmitter and by intracellular kinases, GTP-binding proteins or other second messengers.

Potassium channels are a heterogeneous group of ion channels that are similar in their ability to select for potassium over other ions, but differ in details of activation, inactivation and kinetics (Latorre, R. and Miller, C., J. Memb. Biol., 7:11-30, (1983)). They

contribute significantly to several physiological functions, for example, action potential repolarization, cardiac pacemaking, neuron bursting, and possibly learning and memory (Hodgkin, A.L. and Huxley, A.F., J. Physiol. 117:500-544 (1952)).

The molecular basis for potassium channel function has been greatly clarified by molecular cloning in the *Drosophila* family members of potassium channels, designated *Shaker*, *Shaw*, *Shal*, and *Shal* (Tempel, B.L. et al., Science, 237:770-775 (1987)). Mammalian homologs for all four of these potassium channels have been cloned, (Tempel, B.L. et al., Nature, 332:837-839 (1988)). Subtypes of *Drosophila* potassium channels have been identified. The subtypes in *Drosophila* are largely derived by alternative splicing, (Schwartz, T.L. et al., Nature, 331:137-142 (1988)), whereas subtypes of mammalian potassium channels generally represent distinct genes, although splicing occurs as well. The biophysical properties of these channels can vary with only small alterations in the amino acid sequence, the principal differentiation being between slowly inactivating, "delayed rectifier" channels and rapidly inactivating, A-type channels, (Wei, A. et al., Science, 248:599-603 (1990)). Mammalian homologs of *Drosophila* potassium channels may display either the same or different biophysical properties.

Potassium channels are involved in normal cellular homeostasis and are associated with a variety of disease states and immune responses. Diseases believed to have a particular association with sodium, calcium and potassium channels include autoimmune diseases and other proliferative disorders such as cancers. Autoimmune diseases include rheumatoid arthritis, type-1 diabetes mellitus, multiple sclerosis, myasthenia gravis, systematic lupus erythematosus, Sjogren's syndrome, mixed connective tissue disease among others.

Several classes of potassium channels are involved in maintaining membrane potential and regulating cell volume in diverse cell types, as well as modulating electrical excitability in the nervous system (Lewis, R.S. and Cahalan, M.D., Science, 239:771-775 (1988)). Potassium channels have been shown to control the repolarization phase of action potentials and the pattern of firing neurons and other cells. Potassium currents have been shown to be more diverse than sodium or calcium currents, and also play a central role in determining the way a cell responds to an external stimulus. For instance, the rate of adaptation or delay with which a neuron responds to synaptic input is strongly determined by the presence of different classes of potassium channels. The molecular mechanisms generating potassium channel diversity are best understood in the *Shaker* locus from *Drosophila* which contains 21 exons spanning 130 kb and generates four different potassium channel proteins through alternative splicing of a single primary transcript, (DeCoursey, T.E. et al., J. Gen. Physiol. 89:379-404 (1987)). Expression of these cDNAs in *Xenopus* oocytes gives rise to voltage-dependent potassium currents with distinct physiological properties. The related *Drosophila* potassium channel gene *Shab* also exhibits alternative splicing of a primary transcript giving rise to two distinct proteins (McKinnon, D., and Ceredig, R., J. Exp. Med., 164:1846-1861 (1986)).

PCT Application No. WO 92/02634 discloses the potassium channel expression product of the MK3 gene or a functionally bioactive equivalent thereof and its uses, particularly in combination with identifying immune responses and materials modulating or blocking the same.

A novel potassium channel with unique localizations in the mammalian brain has been identified, cloned and sequenced and has been designated *cdrk*, utilizing a cDNA library prepared from circumvallate papillae of the rat tongue. The *cdrk* channel appears to be a member of the *Shab*'s subfamily,

most closely resembling *cdrk1*. The *cdrk* channel may be important in a variety of excitable tissues, (Hwang, P.M., et al., *Neuron*, 8:473-481 (1992)).

Multiple potassium channel components have been produced by alternative splicing at the *Shaker* locus in *Drosophila*, (Schwarz, T.L., et al., *Nature*, 331-137-142 (1988)).

Members of the RCK potassium channel family have been differentially expressed in the rat nervous system. mRNA'S encoding four members of the RCK potassium channel family, named RCK1, RCK3, RCK4 and RCK5 have been analyzed by RNA blot hybridization experiments using specific RNA probes, (Beckh, S. and Pongs, O., *The EMBO Journal*, 9:777-782 (1990)).

In accordance with one aspect of the present invention, there are provided novel mature polypeptides which are K<sup>+</sup> channel proteins, as well as fragments, analogs and derivatives thereof. The polypeptides of the present invention are of human origin.

In accordance with another aspect of the present invention, there are provided polynucleotides (DNA or RNA) which encode such polypeptides.

In accordance with yet a further aspect of the present invention, there is provided a process for producing such polypeptides by recombinant techniques.

In accordance with yet a further aspect of the present invention, there are provided agonists for the K<sup>+</sup> channel polypeptides which may be used for therapeutic purposes, for example, for treating hypertension, epilepsy, stroke, asthma, parkinson's disease, schizophrenia, anxiety, depression and neurodegeneration.

In accordance with yet a further aspect of the present invention, there are provided antibodies against such polypeptides which may be used as part of a diagnostic assay for detecting autoimmune diseases and cancers.

In accordance with yet another aspect of the present invention, there are provided antagonist/inhibitors to such polypeptides, which may be used to inhibit the action of such polypeptides, for example, in the treatment of migraine headaches, autoimmune diseases, cancer and graft rejection.

These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein.

The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims.

Fig. 1 shows the cDNA sequence and deduced amino acid sequence for the putative mature K<sup>+</sup> channel 1 protein. The standard one-letter abbreviation for amino acids is used.

Fig. 2 shows the cDNA sequence and deduced amino acid sequence for the putative mature K<sup>+</sup> channel 2 protein.

Fig. 3 shows the amino acid homology between K<sup>+</sup> channel 2 protein (top) and Human DRK1 protein (bottom).

In accordance with an aspect of the present invention, there are provided isolated nucleic acids (polynucleotides) which encode for the mature K<sup>+</sup> channel 1 polypeptide having the deduced amino acid sequence of Figure 1 or for the mature polypeptide encoded by the cDNA of the clone deposited as ATCC Deposit No. 75700 on March 4, 1994.

In accordance with another aspect of the present invention, there are provided isolated nucleic acids which encode for the mature K<sup>+</sup> channel 2 polypeptide having the deduced amino acid sequence of Figure 2 or for the mature polypeptide encoded by the cDNA of the clone deposited as ATCC Deposit No. 75830 on July 15, 1994.

Polynucleotides encoding the polypeptides of the present invention may be obtained from brain, skeletal muscle and placental tissues. The polynucleotides of this invention were discovered in a cDNA library derived from human brain.

They are structurally related to the K<sup>+</sup> channel gene family. K<sup>+</sup> channel 1 polypeptide contains an open reading frame encoding a polypeptide of approximately 513 amino acid residues. The polypeptide exhibits the highest degree homology to drk1 protein with approximately 40% identity and 65% similarity over a 400 amino acid stretch.

Polynucleotides encoding the K<sup>+</sup> channel 2 polypeptides of the present invention were discovered in a cDNA library derived from human brain. They are structurally related to the K<sup>+</sup> channel gene family. K<sup>+</sup> channel 2 polypeptide contains an open reading frame encoding a polypeptide of approximately 494 amino acid residues. The polypeptide exhibits the highest degree of homology to human DRK1 protein with approximately 40 % identity and 66 % similarity over a 488 amino acid stretch.

The polynucleotides of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the mature polypeptides may be identical to the coding sequence shown in Figures 1 and 2 or that of the deposited clone or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same mature polypeptides as the DNA of Figures 1 and 2 or the deposited cDNA(s).

The polynucleotides which encode the mature polypeptides of Figures 1 and 2 or the mature polypeptides encoded by the deposited cDNA(s) may include: only the coding sequence for the mature polypeptides; the coding sequence for the mature polypeptides and additional coding sequence such as a leader or secretory sequence; the coding sequence for the mature polypeptides (and optionally additional coding sequence) and



non-coding sequence, such as introns or non-coding sequence 5' and/or 3' of the coding sequence for the mature polypeptides.

Thus, the term "polynucleotide encoding a polypeptide" encompasses a polynucleotide which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.

The present invention further relates to variants of the hereinabove described polynucleotides which encode fragments, analogs and derivatives of the polypeptides having the deduced amino acid sequences of Figures 1 and 2 or the polypeptides encoded by the cDNA of the deposited clones. The variants of the polynucleotides may be naturally occurring allelic variants of the polynucleotides or non-naturally occurring variants of the polynucleotides.

Thus, the present invention includes polynucleotides encoding the same mature polypeptides as shown in Figures 1 and 2 or the same mature polypeptides encoded by the cDNA of the deposited clones as well as variants of such polynucleotides which variants encode for a fragment, derivative or analog of the polypeptides of Figures 1 and 2 or the polypeptides encoded by the cDNA of the deposited clones. Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.

As hereinabove indicated, the polynucleotides may have a coding sequence which is a naturally occurring allelic variant of the coding sequences shown in Figures 1 and 2 or of the coding sequence of the deposited clones. As known in the art, an allelic variant is an alternate form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.

The polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence

which allows for purification of the polypeptides of the present invention. The marker sequence may be a hexahistidine tag supplied by a pQE-9 vector to provide for purification of the mature polypeptides fused to the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., Cell, 37:767 (1984)).

The present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences if there is at least 50% and preferably 70% identity between the sequences. The present invention particularly relates to polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which retain substantially the same biological function or activity as the mature polypeptides encoded by the cDNA of Figures 1 and 2 or the deposited cDNA(s).

The deposit(s) referred to herein will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for purposes of Patent Procedure. These deposits are provided merely as convenience to those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. §112. The sequence of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with any description of sequences herein. A license may be

required to make, use or sell the deposited materials, and no such license is hereby granted.

The present invention further relates to K<sup>+</sup> channel polypeptides which have the deduced amino acid sequences of Figures 1 and 2 or which have the amino acid sequence encoded by the deposited cDNA(s), as well as fragments, analogs and derivatives of such polypeptides.

The terms "fragment," "derivative" and "analog" when referring to the polypeptides of Figures 1 and 2 or that encoded by the deposited cDNA(s), means polypeptides which either retain essentially the same biological function or activity as such polypeptides, or retain the ability to bind the ligand of the K<sup>+</sup> channel polypeptide, however, are a soluble form of such polypeptide and, therefore, elicit no function.

The polypeptides of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide.

The fragment, derivative or analog of the polypeptides of Figures 1 and 2 or that encoded by the deposited cDNA may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptides are fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptides, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptides. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

The present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the  $K^+$  channel protein genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotide may be included in any one of a variety of expression vectors for

expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the E. coli lac or trp, the phage lambda P<sub>L</sub> promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.

The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein.

As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as E. coli, Streptomyces, Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila and Sf9; animal cells such as CHO, COS, HEK 293 or Bowes melanoma; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example. Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pPK223-3, pPK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pPK232-8 and PCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P<sub>R</sub>, P<sub>L</sub> and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate

vector and promoter is well within the level of ordinary skill in the art.

In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation. (Davis, L., Digner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples including the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early

promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK),  $\alpha$ -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may also be employed as a matter of choice.

As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a



selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

The  $K^+$  channel polypeptides can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

The polypeptides of the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.

The present invention relates to an assay for identifying molecules which have a modulating effect, eg. drugs, agonists or antagonists, on the  $K^+$  channel polypeptides of the present invention. Such an assay comprises the steps of providing an expression system that produces a functional  $K^+$  channel expression product encoded by the DNA of the present invention, contacting the expression system or the product of the expression system with one or more molecules to determine its modulating effect on the bioactivity of the product and selecting from the molecules a candidate capable of modulating  $K^+$  channel expression.

Antagonists to the  $K^+$  channel openers, including those identified by the method above, are  $K^+$  channel openers, which

increase  $K^+$  ion flux and, therefore, are useful for treating epilepsy, stroke, hypertension, asthma, Parkinson's disease, schizophrenia, anxiety, depression and neurodegeneration. While applicant does not wish to limit the scientific reasoning behind these therapeutic uses, the high degree of localization of  $K^+$  channel proteins in the brain, nervous system and myocardium,  $K^+$  ion flux through the  $K^+$  channels of the present invention provides an ion balance and a concurrent therapeutic result.

Potential antagonists to the  $K^+$  channel polypeptides of the present invention include an antibody against the  $K^+$  channel polypeptides, or in some cases, an oligonucleotide, which bind to the  $K^+$  channel polypeptides and alter its conformation such that  $K^+$  ions do not pass therethrough. Soluble  $K^+$  Channel 1 polypeptides may also be used as antagonists by administering them into circulation to bind free  $K^+$  ions and, therefore, reduce their concentration in vivo.

Potential antagonists also include antisense constructs produced by antisense technology. Antisense technology controls gene expression through triple-helix formation, etc. The number of  $K^+$  Channels may be reduced through antisense technology, which controls gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes for the mature polypeptides of the present invention, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix -see Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al, Science, 241:456 (1988); and Dervan et al., Science, 251: 1360 (1991)), thereby

preventing transcription and the production of the  $K^+$  channel polypeptides. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the  $K^+$  channel polypeptides (antisense - Okano, J. Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). The antisense constructs can be delivered to cells by procedures known in the art such that the antisense RNA or DNA may be expressed *in vivo*.

Another example of potential antagonists include a small molecule which binds to and occupies the opening in the  $K^+$  channel polypeptide thereby not allowing  $K^+$  ions to pass therethrough, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small peptides or peptide-like molecules.

The antagonists which exert their effect upon the  $K^+$  channel polypeptides may be used to treat autoimmune diseases which result from abnormal cells of the immune system destroying target tissues, either by direct killing or by producing autoantibodies. In a normal immune response the  $n$  channel type of  $K^+$  channel proteins are increased upwards of ten fold in normal T cells. Accordingly, the antagonist/inhibitors may be employed to treat autoimmune diseases such as AIDS, SLE, diabetes mellitus, multiple sclerosis and lymphocyte-mediated immune reaction against transplantation antigens. The antagonist/inhibitors may also be used to treat cell-proliferative conditions, such as cancer and tumorigenicity, which have a similar association with immunologic factors. The antagonist/inhibitors may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as hereinafter described.

The agonists or antagonists of the  $K^+$  channel polypeptides of the present invention may be employed in combination with a suitable pharmaceutical carrier to

comprise a pharmaceutical composition. Such compositions comprise a therapeutically effective amount of the agonist or antagonist, as the case may be, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should suit the mode of administration.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

The pharmaceutical compositions may be administered in a convenient manner such as by the intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes. The compositions are administered in an amount which is effective for treating and/or prophylaxis of the specific indication. In general, the compositions will be administered in an amount of at least about 10  $\mu\text{g/kg}$  body weight and in most cases they will be administered in an amount not in excess of about 8 mg/Kg body weight per day. In most cases, the dosage is from about 10  $\mu\text{g/kg}$  to about 1 mg/kg body weight daily, taking into account the routes of administration, symptoms, etc.

The agonists or antagonists which are polypeptides may be employed in accordance with the present invention by expression of such polypeptides in vivo, which is often referred to as "gene therapy."

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) encoding a

polypeptide *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, cells may be engineered by procedures known in the art by use of a retroviral particle containing RNA encoding a polypeptide of the present invention.

Similarly, cells may be engineered *in vivo* for expression of a polypeptide *in vivo* by, for example, procedures known in the art. As known in the art, a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the present invention may be administered to a patient for engineering cells *in vivo* and expression of the polypeptide *in vivo*. These and other methods for administering a polypeptide of the present invention by such method should be apparent to those skilled in the art from the teachings of the present invention. For example, the expression vehicle for engineering cells may be other than a retrovirus, for example, an adenovirus which may be used to engineer cells *in vivo* after combination with a suitable delivery vehicle.

The sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the cDNA is used to rapidly select primers that do not span more than one exon in the genomic

DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include *in situ* hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 500 or 600 bases; however, clones larger than 2,000 bp have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. FISH requires use of the clones from which the EST was derived, and the longer the better. For example, 2,000 bp is good, 4,000 is better, and more than 4,000 is probably not necessary to get good results a reasonable percentage of the time. For a review of this technique, see Verma et al., *Human Chromosomes: a Manual of Basic Techniques*, Pergamon Press, New York (1988).

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, *Mendelian Inheritance in Man* (available on line through Johns Hopkins University Welch Medical Library).

With current resolution of physical mapping and genetic mapping techniques, a cDNA precisely localized to a chromosomal region associated with the disease could be one of between 50 and 500 potential causative genes. (This assumes 1 megabase mapping resolution and one gene per 20 kb).

The polypeptides, their fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. These antibodies can be, for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.

Antibodies generated against the polypeptides corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptides itself. In this manner, even a sequence encoding only a fragment of the polypeptides can be used to generate antibodies binding the whole native polypeptides. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.

For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).



Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention.

In accordance with another aspect of the present invention, there is provided an assay for diagnosing a diseased state associated with  $K^+$  channel expression mediated T cell activation comprising providing T cells containing  $K^+$  channels from a test individual, identifying activated T cells from among the population of T cells and measuring the activation of the T cells relative to the total T cell population by measuring  $K^+$  channel expression using labeling means based on a functionally bioactive product of DNA encoding the genes of the present invention. This assay may be used to detect autoimmune diseases and cancer, since T cells associated with these conditions have an elevated number of  $K^+$  channels.

The present invention will be further described with reference to the following examples; however, it is to be understood that the present invention is not limited to such examples. All parts or amounts, unless otherwise specified, are by weight.

In order to facilitate understanding of the following examples certain frequently occurring methods and/or terms will be described.

"Plasmids" are designated by a lower case p preceded and/or followed by capital letters and/or numbers. The starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures. In addition, equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan.

"Digestion" of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan. For analytical purposes, typically 1  $\mu$ g of plasmid or DNA fragment is used with about 2 units of enzyme in about 20  $\mu$ l of buffer solution. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50  $\mu$ g of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37°C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion the reaction is electrophoresed directly on a polyacrylamide gel to isolate the desired fragment.

Size separation of the cleaved fragments is performed using 8 percent polyacrylamide gel described by Goeddel, D. et al., *Nucleic Acids Res.*, 8:4057 (1980).

"Oligonucleotides" refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.

"Ligation" refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (Maniatis, T., et al., *Id.*, p. 146). Unless otherwise provided, ligation may be accomplished using known buffers and conditions with 10 units to T4 DNA ligase

("ligase") per 0.5  $\mu$ g of approximately equimolar amounts of the DNA fragments to be ligated.

Unless otherwise stated, transformation was performed as described in the method of Graham, F. and Van der Eb, A., *Virölogy*, 52:456-457 (1973).

#### Example 1

##### Bacterial Expression and Purification of K<sup>+</sup> Channel 1 Protein

The DNA sequence encoding for the K<sup>+</sup> channel 1 polypeptides of the present invention, ATCC # 75700, is initially amplified using PCR oligonucleotide primers corresponding to the 5' and sequences of the processed K<sup>+</sup> channel 1 protein (minus the signal peptide sequence) and the vector sequences 3' to the K<sup>+</sup> channel protein gene. Additional nucleotides corresponding to K<sup>+</sup> channel 1 protein are added to the 5' and 3' sequences respectively. The 5' oligonucleotide primer has the sequence 5' GACTAAAGCTTAATGACCCCTCTTACCGGG 3' contains a Hind III restriction enzyme site followed by 17 nucleotides of the coding sequence starting from the presumed terminal amino acid of the protein codon. The 3' sequence 3' GAACTTCTAGACCGGCTCAGTCATTGTC 5' contains complementary sequences to an Xba I restriction enzyme site and is followed by 18 nucleotides of the non-coding sequence located 3' to the K<sup>+</sup> channel 1 protein DNA insert and to a pBluescript SK<sup>+</sup> vector sequence located 3' to the K<sup>+</sup> channel 1 protein DNA insert. The restriction enzyme sites correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc. 9259 Eton Avenue, Chatsworth, CA, 91311). pQE-9 encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter operator (P/O), a ribosome binding site (RBS), a 6-His tag and restriction enzyme sites. pQE-9 is then digested with Hind III and Xba I. The amplified sequences are ligated

into pQE-9 and are inserted in frame with the sequence encoding for the histidine tag and the RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 available from Qiagen under the trademark M15/rep 4 by the procedure described in Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, (1989). M15/rep4 contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies were selected. Plasmid DNA is isolated and confirmed by restriction analysis. Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG ("Isopropyl-B-D-thiogalacto pyranoside") is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression. Cells are grown an extra 3 to 4 hours. Cells are then harvested by centrifugation. The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl. After clarification, solubilized K<sup>+</sup> channel protein is purified from this solution by chromatography on a Nickel-Chelate column under conditions that allow for tight binding by proteins containing the 6-His tag (Hochuli, E. et al., J. Chromatography 411:177-184 (1984)). K<sup>+</sup> channel 1 protein is eluted from the column in 6 molar guanidine HCl pH 5.0 and for the purpose of renaturation adjusted to 3 molar guanidine HCl, 100mM sodium phosphate, 10 mmolar glutathione (reduced) and 2 mmolar glutathione (oxidized). After incubation in this solution for 12 hours the protein is dialyzed to 10 mmolar sodium phosphate.

Example 2Cloning and expression of K<sup>+</sup> channel 1 protein using the baculovirus expression system

The DNA sequence encoding the full length K<sup>+</sup> channel 1 protein, ATCC # 75700, was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene:

The 5' primer has the sequence 5' CGGGATCCCTCCATGACCTCTTACCGGA 3' and contains a BamHI restriction enzyme site followed by 4 nucleotides resembling an efficient signal for the initiation of translation in eukaryotic cells (J. Mol. Biol. 1987, 196, 947-950, Kozak, M.), and just behind the first 18 nucleotides of the K<sup>+</sup> channel 1 gene (the initiation codon for translation "ATG" is underlined).

The 3' primer has the sequence 5' CGGGATCCCGCTCAGTTATTGTCTCTGGT 3' and contains the cleavage site for the restriction endonuclease BamHI and 18 nucleotides complementary to the 3' non-translated sequence of the K<sup>+</sup> channel 1 gene. The amplified sequences were isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment was then digested with the endonuclease BamHI and then purified on a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.). This fragment is designated F2.

The vector PRG1 (modification of pVL941 vector, discussed below) is used for the expression of the K<sup>+</sup> channel 1 protein using the baculovirus expression system (for review see: Summers, M.D. and Smith, G.E. 1987, A manual of methods for baculovirus vectors and insect cell culture procedures, Texas Agricultural Experimental Station Bulletin No. 1555). This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by the recognition sites for the

restriction endonuclease BamH1. The polyadenylation site of the simian virus (SV)40 is used for efficient polyadenylation. For an easy selection of recombinant viruses the beta-galactosidase gene from E.coli is inserted in the same orientation as the polyhedrin promoter followed by the polyadenylation signal of the polyhedrin gene. The polyhedrin sequences are flanked at both sides by viral sequences for the cell-mediated homologous recombination of cotransfected wild-type viral DNA. Many other baculovirus vectors could be used in place of pRG1 such as pAc373, pVL941 and pAcIM1 (Luckow, V.A. and Summers, M.D., Virology, 170:31-39).

The plasmid was digested with the restriction enzymes BamH1 and then dephosphorylated using calf intestinal phosphatase by procedures known in the art. The DNA was then isolated from a 1% agarose gel and purified again on a 1% agarose gel. This vector DNA is designated V2.

Fragment F2 and the dephosphorylated plasmid V2 were ligated with T4 DNA ligase. E.coli HB101 cells were then transformed and bacteria identified that contained the plasmid (pBack+ channel 1) with the K+ channel 1 gene using the enzymes BamH1. The sequence of the cloned fragment was confirmed by DNA sequencing.

5 µg of the plasmid pBack+ channel 1 were cotransfected with 1.0 µg of a commercially available linearized baculovirus ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA.) using the lipofection method (Felgner et al. Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987)).

1µg of BaculoGold™ virus DNA and 5 µg of the plasmid pBack+ channel 1 were mixed in a sterile well of a microtiter plate containing 50 µl of serum free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards 10 µl Lipofectin plus 90 µl Grace's medium were added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture was added dropwise to the Sf9 insect

cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1ml Grace' medium without serum. The plate was rocked back and forth to mix the newly added solution. The plate was then incubated for 5 hours at 27°C. After 5 hours the transfection solution was removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum was added. The plate was put back into an incubator and cultivation continued at 27°C for four days.

After four days the supernatant was collected and a plaque assay performed similar as described by Summers and Smith (supra). As a modification an agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) was used which allows an easy isolation of blue stained plaques. (A detailed description of a "plaque assay" can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10).

Four days after the serial dilution of the viruses was added to the cells, blue stained plaques were picked with the tip of an Eppendorf pipette. The agar containing the recombinant viruses was then resuspended in an Eppendorf tube containing 200 µl of Grace's medium. The agar was removed by a brief centrifugation and the supernatant containing the recombinant baculoviruses was used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes were harvested and then stored at 4°C.

Sf9 cells were grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells were infected with the recombinant baculovirus V-K+ channel 1 at a multiplicity of infection (MOI) of 2. Six hours later the medium was removed and replaced with SF900 II medium minus methionine and cysteine (Life Technologies Inc., Gaithersburg). 42 hours later 5 µCi of <sup>35</sup>S-methionine and 5 µCi <sup>35</sup>S cysteine (Amersham) were added. The cells were further incubated for 16 hours

before they were harvested by centrifugation and the labelled proteins visualized by SDS-PAGE and autoradiography.

### Example 3

#### Expression of Recombinant K<sup>+</sup> channel 1 protein in COS cells

The expression of plasmid, pK<sup>+</sup> channel 1 HA is derived from a vector pcDNA1/Amp (Invitrogen) containing: 1) SV40 origin of replication, 2) ampicillin resistance gene, 3) E.coli replication origin, 4) CMV promoter followed by a polylinker region, a SV40 intron and polyadenylation site. A DNA fragment encoding the entire K<sup>+</sup> channel 1 protein and a HA tag fused in frame to its 3' end was cloned into the polylinker region of the vector, therefore, the recombinant protein expression is directed under the CMV promoter. The HA tag correspond to an epitope derived from the influenza hemagglutinin protein as previously described (I. Wilson, H. Niman, R. Heighen, A. Cherenson, M. Connolly, and R. Lerner, 1984, Cell 37, 767). The infusion of HA tag to our target protein allows easy detection of the recombinant protein with an antibody that recognizes the HA epitope.

The plasmid construction strategy is described as follows:

The DNA sequence encoding for K<sup>+</sup> channel 1 protein, ATCC # 75700, was constructed by PCR on the full-length gene cloned using two primers: the 5' primer 5' GTCCAAGCTTGCCACCATGACCCTCTTACCCGGA 3' contains a HindIII site followed by 18 nucleotides of K<sup>+</sup> channel 1 coding sequence starting from the initiation codon; the 3' sequence 5' CTAGCTCGAGTCAAGCGTAGTCTGGGACGTCGTATGGGTAGCAGTTATTGTCTCTGGT 3' contains complementary sequences to an XhoI site, translation stop codon, HA tag and the last 15 nucleotides of the K<sup>+</sup> channel 1 coding sequence (not including the stop codon). Therefore, the PCR product contains a HindIII site, K<sup>+</sup> channel 1 coding sequence followed by HA tag fused in frame, a translation termination stop codon next to the HA tag, and



an Xho I site. The PCR amplified DNA fragment and the vector, pcDNA1/Amp, were digested with HindIII and XhoI restriction enzymes and ligated. The ligation mixture was transformed into E. coli strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, CA 92037) the transformed culture was plated on ampicillin media plates and resistant colonies were selected. Plasmid DNA was isolated from transformants and examined by restriction analysis for the presence of the correct fragment. For expression of the recombinant K<sup>+</sup> channel 1, COS cells were transfected with the expression vector by DEAE-DEXTRAN method. (J. Sambrook, E. Fritsch, T. Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, (1989)). The expression of the K<sup>+</sup> channel 1 HA protein was detected by radiolabelling and immunoprecipitation method. (E. Harlow, D. Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, (1988)). Cells were labelled for 8 hours with <sup>35</sup>S-cysteine two days post transfection. Culture media were then collected and cells were lysed with detergent (RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 1% NP-40, 0.5% DOC, 50mM Tris, pH 7.5). (Wilson, I. et al., Id. 37:767 (1984)). Both cell lysate and culture media were precipitated with a HA specific monoclonal antibody. Proteins precipitated were analyzed on 15% SDS-PAGE gels.

#### Example 4

#### Cloning and expression of K<sup>+</sup> channel 2 protein using the baculovirus expression system

The DNA sequence encoding the full length K<sup>+</sup> channel 2 protein, ATCC # 75830, was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene:

The 5' primer has the sequence 5' CGGGATCCCTCCATGGACGGGTCCGGGGAG 3' and contains a BamHI restriction enzyme site followed by 4 nucleotides resembling

an efficient signal for the initiation of translation in eukaryotic cells (J. Mol. Biol. 1987, 196, 947-950, Kozak, M.), and just behind the first 18 nucleotides of the K<sup>+</sup> channel 2 gene (the initiation codon for translation "ATG" is underlined).

The 3' primer has the sequence 5' CCGGATCCCGCTCACTTGCAACTCTGGAG 3' and contains the cleavage site for the restriction endonuclease BamH1 and 18 nucleotides complementary to the 3' non-translated sequence of the K<sup>+</sup> channel 2 gene. The amplified sequences were isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment was then digested with the endonuclease BamH1 and then purified again on a 1% agarose gel. This fragment is designated F2.

The vector pRG1 (modification of pVL941 vector, discussed below) is used for the expression of the K<sup>+</sup> channel 2 protein using the baculovirus expression system (for review see: Summers, M.D. and Smith, G.E. 1987, A manual of methods for baculovirus vectors and insect cell culture procedures, Texas Agricultural Experimental Station Bulletin No. 1555). This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by the recognition sites for the restriction endonuclease BamH1. The polyadenylation site of the simian virus (SV)40 is used for efficient polyadenylation. For an easy selection of recombinant viruses the beta-galactosidase gene from E.coli is inserted in the same orientation as the polyhedrin promoter followed by the polyadenylation signal of the polyhedrin gene. The polyhedrin sequences are flanked at both sides by viral sequences for the cell-mediated homologous recombination of cotransfected wild-type viral DNA. Many other baculovirus vectors could be used in place of pRG1 such as pAc373, pVL941

and pAcIM1 (Luckow, V.A. and Summers, M.D., Virology, 170:31-39).

The plasmid was digested with the restriction enzymes BamH1 and then dephosphorylated using calf intestinal phosphatase by procedures known in the art. The DNA was then isolated from a 1% agarose gel and purified again on a 1% agarose gel. This vector DNA is designated V2.

Fragment F2 and the dephosphorylated plasmid V2 were ligated with T4 DNA ligase. E.coli HB101 cells were then transformed and bacteria identified that contained the plasmid (pBack+ channel 2) with the K+ channel 2 gene using the enzymes BamH1. The sequence of the cloned fragment was confirmed by DNA sequencing.

5 µg of the plasmid pBack+ channel 2 were cotransfected with 1.0 µg of a commercially available linearized baculovirus ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA.) using the lipofection method (Felgner et al. Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987)).

1 µg of BaculoGold™ virus DNA and 5 µg of the plasmid pBack+ channel 2 were mixed in a sterile well of a microtiter plate containing 50 µl of serum free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards 10 µl Lipofectin plus 90 µl Grace's medium were added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture was added dropwise to the Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1ml Grace' medium without serum. The plate was rocked back and forth to mix the newly added solution. The plate was then incubated for 5 hours at 27°C. After 5 hours the transfection solution was removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum was added. The plate was put back into an incubator and cultivation continued at 27°C for four days.

After four days the supernatant was collected and a plaque assay performed similar as described by Summers and

Smith (supra). As a modification an agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) was used which allows an easy isolation of blue stained plaques. (A detailed description of a "plaque assay" can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10).

Four days after the serial dilution of the viruses was added to the cells, blue stained plaques were picked with the tip of an Eppendorf pipette. The agar containing the recombinant viruses was then resuspended in an Eppendorf tube containing 200  $\mu$ l of Grace's medium. The agar was removed by a brief centrifugation and the supernatant containing the recombinant baculoviruses was used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes were harvested and then stored at 4°C.

Sf9 cells were grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells were infected with the recombinant baculovirus V-K+ channel 2 at a multiplicity of infection (MOI) of 2. Six hours later the medium was removed and replaced with SF900 II medium minus methionine and cysteine (Life Technologies Inc., Gaithersburg). 42 hours later 5  $\mu$ Ci of  $^{35}$ S-methionine and 5  $\mu$ Ci  $^{35}$ S cysteine (Amersham) were added. The cells were further incubated for 16 hours before they were harvested by centrifugation and the labelled proteins visualized by SDS-PAGE and autoradiography.

#### Example 5

##### Expression of Recombinant K+ channel 2 protein in COS cells

The expression of plasmid, pK+ channel 2 HA is derived from a vector pcDNAI/Amp (Invitrogen) containing: 1) SV40 origin of replication, 2) ampicillin resistance gene, 3) E.coli replication origin, 4) CMV promoter followed by a polylinker region, a SV40 intron and polyadenylation site. A DNA fragment encoding the entire K+ channel 2 protein and

a HA tag fused in frame to its 3' end was cloned into the polylinker region of the vector, therefore, the recombinant protein expression is directed under the CMV promoter. The HA tag correspond to an epitope derived from the influenza hemagglutinin protein as previously described (I. Wilson, H. Niman, R. Heighten, A. Cherenson, M. Connolly, and R. Lerner, 1984, Cell 37, 767). The infusion of HA tag to our target protein allows easy detection of the recombinant protein with an antibody that recognizes the HA epitope.

The plasmid construction strategy is described as follows:

The DNA sequence encoding for K<sup>+</sup> channel 2 protein, ATCC # 75830, was constructed by PCR on the full-length gene cloned using two primers: the 5' primer 5' GTCCAAGCTTGCCACCATGGACGGGTCCGGGGAG 3' contains a HindIII site followed by 18 nucleotides of K<sup>+</sup> channel 2 coding sequence starting from the initiation codon; the 3' sequence 5' CTAGCTCGAGTCAAGCGTAGTCTGGGACGTCGTATGGGTAGCACTTGCAACTCTGGAGCCG 3' contains complementary sequences to an XhoI site, translation stop codon, HA tag and the last 18 nucleotides of the K<sup>+</sup> channel 2 coding sequence (not including the stop codon). Therefore, the PCR product contains a HindIII site, K<sup>+</sup> channel 2 coding sequence followed by HA tag fused in frame, a translation termination stop codon next to the HA tag, and an Xho I site. The PCR amplified DNA fragment and the vector, pcDNA1/Amp, were digested with HindIII and XhoI restriction enzymes and ligated. The ligation mixture was transformed into E. coli strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, CA 92037) the transformed culture was plated on ampicillin media plates and resistant colonies were selected. Plasmid DNA was isolated from transformants and examined by restriction analysis for the presence of the correct fragment. For expression of the recombinant K<sup>+</sup> channel 2, COS cells were transfected with the expression vector by

DEAE-DEXTRAN method. (J. Sambrook, E. Fritsch, T. Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, (1989)). The expression of the K<sup>+</sup> channel 2 HA protein was detected by radiolabelling and immunoprecipitation method. (E. Harlow, D. Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, (1988)). Cells were labelled for 8 hours with <sup>35</sup>S-cysteine two days post transfection. Culture media were then collected and cells were lysed with detergent (RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 1% NP-40, 0.5% DOC, 50mM Tris, pH 7.5). (Wilson, I. et al., Id. 37:767 (1984)). Both cell lysate and culture media were precipitated with a HA specific monoclonal antibody. Proteins precipitated were analyzed on 15% SDS-PAGE gels.

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, within the scope of the appended claims, the invention may be practiced otherwise than as particularly described.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: LI, ET AL.
- (ii) TITLE OF INVENTION: Potassium Channel Protein 1  
and 2
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: CARELLA, BYRNE, BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN
  - (B) STREET: 6 BECKER FARM ROAD
  - (C) CITY: ROSELAND
  - (D) STATE: NEW JERSEY
  - (E) COUNTRY: USA
  - (F) ZIP: 07068
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: 3.5 INCH DISKETTE
  - (B) COMPUTER: IBM PS/2
  - (C) OPERATING SYSTEM: MS-DOS
  - (D) SOFTWARE: WORD PERFECT 5.1
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE: SUBMITTED HEREWITH
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: FERRARO, GREGORY D.

(B) REGISTRATION NUMBER: 36,134

(C) REFERENCE/DOCKET NUMBER: 325800-105

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 201-994-1700

(B) TELEFAX: 201-994-1744

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 2127 BASE PAIRS

(B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: SINGLE

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ACAAAAGCTG	GAGCTCCACC	GCGGTGCGGC	CGCTCTAGAA	CTAGTGGATC	CCCCGGGCTG	60
CAGGGGCTCC	GAGGGCGGGA	GCTGAGCCGG	GCCCCGGGAC	CGAAGTTTGG	CGGCGGCTCC	120
GGGAGGCAGA	GCGGGCTCCC	CGGGCGACTT	CCAGGCCCTT	CTCGCGTCCT	CGCCCCGGAC	180
CCGTGGGCAG	TCGGGGGGGA	CGGAAGCCGC	GGCCGGGCCA	ACTCCGAGGC	GGGGACGCCG	240
CGACGGGAAC	TTGAGGCCCG	AGAGGGATGT	GAAGGCCCAA	AATGACCCTC	TTACCGGGAG	300
ACAATTCTGA	CTACGACTAC	AGCGCGCTGA	GCTGCACCTC	GGACGCCTCC	TTCCACCCGG	360
CCTTCCTCCC	GCAGCGCCAG	GCCATCAAGG	GCGCGTTCTA	CCGCCGGGCG	CAGCGGCTGC	420
GGCCGCAGGA	TGAGCCCCGC	CAGGGCTGTC	AGCCCCGAGG	CCGCCGCCGT	CGGATCATCA	480
TCAACGTAGG	CGGCATCAAG	TACTCGCTGC	CCTGGACCAC	GCTGGACGAG	TTCCCGCTGA	540
CGCGCCTGGG	CCAGCTCAAG	GCCTGCACCA	ACTTCGACGA	CATCCTCAAC	GTGTGCGATG	600
ACTACGACGT	CACCTGCAAC	GAGTTCTTCT	TCGACCGCAA	CCCGGGGGCC	TTCGGCACTA	660
TCCTGACCTT	CCTGCGCGCG	GGCAAGCTGC	GGCTGCTGCG	CGAGATGTGC	GCGCTGTCCT	720
TCCAGGAGGA	GCTGCTGTAC	TGGGGCATCG	CGGAGGACCA	CCTGGACGGC	TGCTGCAAGC	780
GCCGCTACCT	GCAGAAGATT	GAGGAGTTTC	CGGAGATGGT	GGAGCGGGAG	GAAGAGGACG	840
ACGCGCTGGA	CAGCGAGGGC	CGCGACAGCG	AGGGCCCCGC	CGAGGGCGAG	GGCCGCCTGG	900
GGCGCTGCAT	GCGGCGACTG	CGCGACATGG	TGGAGAGGCC	GCACTCGGGG	CTGCCTGGCA	960
AGGTGTTTCG	CTGCCTGTTC	GTGCTCTTCG	TGACCGTCAC	CGCCGTCAAC	CTCTCCGTCA	1020
GCACCTTGCC	CAGCCTGAGG	GAGGAGGAGG	AGCAGGGCCA	CTGTTCCAG	ATGTGCCACA	1080
ACGTCTTCAT	CGTGGAGTCG	GTGTGCGTGG	GCTGGTTCTC	CCTGGAGTTC	CTCCTGCGGC	1140
TCATTCAGGC	GCCCAGCAAG	TTGCGCTTCC	TGCGGAGCCC	GCTGACGCTG	ATCGACCTGG	1200



TGGCCATCCT GCCCTACTAC ATCACGCTGC TGGTGGACGG CGCCGCCGCA GGCCGTGCA 1260  
 AGCCCGGCGC GGGCAACAGC TACCTGGACA AGGTGGGGCT GGTGCTGCGC GTGCTGCGG 1320  
 CGCTGCGCAT CCTGTACGTG ATGCGCCTGG CGCGCCACTC CCTGGGGCTG CAGACGCTGG 1380  
 GGCTCACGGC CCGCGCTGC ACCCGCGAGT TCGGGCTCCT GCTGCTCTTC CTCTGCGTGG 1440  
 CCATCGCCCT CTTGCGGCCC CTGCTCTACG TCATCGAGAA CGAGATGGCC GACAGCCCCG 1500  
 AGTTCAACAG CATCCCTGCC TGCTACTGGT GGGCTGTCAT CACCATGACG ACGGTGGACT 1560  
 ATGGCGACAT GGTCCCCAGG AGCAGCCCGG GCCAGGTAGT GGCCCTGAGC AGCATCCTGA 1620  
 GCGGCATCCT GCTCATGGCC TTCCCAGTCA CCTCCATCTT CCACACCTTC TCCCCCTCCT 1680  
 ACCTGGAGCT CAAACAGGAG CAAGAGAGGG TGATGTTCCG GAGGGCGCAG TTCCTCATCA 1740  
 AAACCAAGTC GCAGCTGAGC GTGTCCCAGG ACAGTGACAT CTTGTTCCGA AGTGCTCCT 1800  
 CGGACACCAG AGACAATAAC TGAGCGCGGA GGACACGCCT GCCCTGCCTG CCATCTGTGG 1860  
 CCCGAAGCCA TTGCCATCCA CTGCAGACGC CTGGAGAGGG ACAGGCCGCT TCCGAGTGCA 1920  
 GTCCTGGCGC AGCACCGACT CCCACGCACC CGGGGAAGGA CACCCTCACT CCCACACCCC 1980  
 GGGGAAGAACA CTAGAACATC AGCAGAGGGG CCCTGCCCCCT CCGCCTGCAG CCGTGAAAGG 2040  
 AAGCTGGGTC ATCAGCCCCAG CCCGCCCCAC CCCAGCCCCT ATGTGTGTTT CCCTCAATAA 2100  
 GGAGATGCCT TGTCTTTTC ACCATGC 2127

## (3) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 513 AMINO ACIDS

(B) TYPE: AMINO ACID

(C) STRANDEDNESS:

(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Thr Leu Leu Pro Gly Asp Asn Ser Asp Tyr Asp Tyr Ser Ala  
 5 10 15  
 Leu Ser Cys Thr Ser Asp Ala Ser Phe His Pro Ala Phe Leu Pro  
 20 25 30  
 Gln Arg Gln Ala Ile Lys Gly Ala Phe Tyr Arg Arg Ala Gln Arg  
 35 40 45  
 Leu Arg Pro Gln Asp Glu Pro Arg Gln Gly Cys Gln Pro Glu Asp  
 50 55 60  
 Arg Arg Arg Arg Ile Ile Ile Asn Val Gly Gly Ile Lys Tyr Ser

65	70	75
Leu Pro Trp Thr Thr Leu Asp Glu Phe Pro Leu Thr Arg Leu Gly		
80	85	90
Gln Leu Lys Ala Cys Thr Asn Phe Asp Asp Ile Leu Asn Val Cys		
95	100	105
Asp Asp Tyr Asp Val Thr Cys Asn Glu Phe Phe Phe Asp Arg Asn		
110	115	120
Pro Gly Ala Phe Gly Thr Ile Leu Thr Phe Leu Arg Ala Gly Lys		
125	130	135
Leu Arg Leu Leu Arg Glu Met Cys Ala Leu Ser Phe Gln Glu Glu		
140	145	150
Leu Leu Tyr Trp Gly Ile Ala Glu Asp His Leu Asp Gly Cys Cys		
155	160	165
Lys Arg Arg Tyr Leu Gln Lys Ile Glu Glu Phe Ala Glu Met Val		
170	175	180
Glu Arg Glu Glu Glu Asp Asp Ala Leu Asp Ser Glu Gly Arg Asp		
185	190	195
Ser Glu Gly Pro Ala Glu Gly Glu Gly Arg Leu Gly Arg Cys Met		
200	205	210
Arg Arg Leu Arg Asp Met Val Glu Arg Pro His Ser Gly Leu Pro		
215	220	225
Gly Lys Val Phe Ala Cys Leu Ser Val Leu Phe Val Thr Val Thr		
230	235	240
Ala Val Asn Leu Ser Val Ser Thr Leu Pro Ser Leu Arg Glu Glu		
245	250	255
Glu Glu Gln Gly His Cys Ser Gln Met Cys His Asn Val Phe Ile		
260	265	270
Val Glu Ser Val Cys Val Gly Trp Phe Ser Leu Glu Phe Leu Leu		
275	280	285
Arg Leu Ile Gln Ala Pro Ser Lys Phe Ala Phe Leu Arg Ser Pro		
290	295	300
Leu Thr Leu Ile Asp Leu Val Ala Ile Leu Pro Tyr Tyr Ile Thr		
305	310	315
Leu Leu Val Asp Gly Ala Ala Ala Gly Arg Arg Lys Pro Gly Ala		
320	325	330

Gly Asn Ser Tyr Leu Asp Lys Val Gly Leu Val Leu Arg Phe Leu	335	340	345
Arg Ala Leu Arg Ile Leu Tyr Val Met Arg Leu Ala Arg His Ser	350	355	360
Leu Gly Leu Gln Thr Leu Gly Leu Thr Ala Arg Arg Cys Thr Arg	365	370	375
Glu Phe Gly Leu Leu Leu Leu Phe Leu Cys Val Ala Ile Ala Leu	380	385	390
Phe Ala Pro Leu Leu Tyr Val Ile Glu Asn Glu Met Ala Asp Ser	395	400	405
Pro Glu Phe Thr Ser Ile Pro Ala Cys Tyr Trp Trp Ala Val Ile	410	415	420
Thr Met Thr Thr Val Asp Tyr Gly Asp Met Val Pro Arg Ser Thr	425	430	435
Pro Gly Gln Val Val Ala Leu Ser Ser Ile Leu Ser Gly Ile Leu	440	445	450
Leu Met Ala Phe Pro Val Thr Ser Ile Phe His Thr Phe Ser Pro	455	460	465
Ser Tyr Leu Glu Leu Lys Gln Glu Gln Glu Arg Val Met Phe Arg	470	475	480
Arg Ala Gln Phe Leu Ile Lys Thr Lys Ser Gln Leu Ser Val Ser	485	490	495
Gln Asp Ser Asp Ile Leu Phe Gly Ser Ala Ser Ser Asp Thr Arg	500	505	510

Asp Asn Asn

(4) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH: 2483 BASE PAIRS
  - (B) TYPE: NUCLEIC ACID
  - (C) STRANDEDNESS: SINGLE
  - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGTCGCAACC	CCTCGGTGAC	CCGCTGCGCC	CGAGGAGGGG	CCGGCGGTGC	GCGGTGGTGG	60
CGGCGGGCGC	GGCAGCTGTG	CCCGTCTGCC	CAAGGGTTAA	TCCGTCCCCT	GCAGCTGCCG	120
CGCGTGCCCT	GCAGAATTTC	ACCAGAAGAG	GGTACAGTTT	GAAAAGCTCC	TGACGTCAGG	180
CTGGAATTCC	TATTGTGTTT	AGAAAAGGCT	CGGGCAAAGC	CAGCCCAAGT	TCGCTCTCTG	240
CACACCTCGA	GCACCTCGCG	GACGGCGTGG	GTCCGCCAGC	TCCGGGACCT	GCCGCGCGCTG	300
CCTGCGCGCC	CCGGGGCGGA	GGACGGTGCC	AGCCGCCAC	GAGGAGACCC	CGCTCCCGCA	360
GGAGGCGGAG	CTGAAGCGGC	GGAGCGCGCC	GCCAGCCAGC	CGGGGTGAGT	GCCCCGGGCG	420
AGGCCGGCGG	CCGCCAAAGC	CCCCGCGGGT	TCGTCCGGGC	GCCCGGATGC	CAGCCCCGAG	480
CCCCGCGGCC	GGGTGCATGC	CTCCCCCGCG	GCGCGCCCCC	GCAGGCTGCT	GCCCGCTGTG	540
ACCGCCCTTC	CCCGCAGGCG	GGCGCCGGCC	AGGCTCTCCC	ACGAGATACG	ACGCACGGGT	600
GGCACCCGCC	GGACCCCCAA	CGACAACGGC	GGCGACGTCT	GCAGGGGGCG	CGGGGCGGAG	660
CCTGCGAGGG	CGCGCACGGG	GAGGATGGAC	GGGTCCGGGG	AGCGCAGCCT	CCCGGAGCCG	720
GGCAGCCAGA	GCTCCGCTGC	CAGCGACGAC	ATAGAGATAG	TCGTCAACGT	GGGGGGCGTG	780
CGGCAGGTGC	TGTACGGGGA	CCTCCTCAGT	CAGTACCCTG	AGACCCGGCT	GGCGGAGCTC	840
ATCAACTGCT	TGGCTGGGGG	CTACGACACC	ATCTTCTCCC	TGTGCGACGA	CTACGACCCC	900
GGCAAGCGCG	AGTTCTACTT	TGACAGGGAC	CCGGACGCCT	TCAAGTGTGT	CATCGAGGTG	960
TACTATTTTC	GGGAGGTCCA	CATGAAGAAG	GGCATCTGCC	CCATCTGCTT	CAAGAACGAG	1020
ATGGACTTCT	GGAAGGTGGA	CCTCAAGTTC	CTGGACGACT	GTTGCAAGAG	CCACCTGAGC	1080
GAGAAGCGCG	AGGAGCTGGA	GGAGATCGCG	CGCCGCGTGC	AGCTCATCCT	GGACGACCTG	1140
GGCGTGAGCG	CGGCCGAGGG	CCGCTGGCGC	CGCTGCCAGA	AGTGCGTCTG	GAAGTTCCCTG	1200
GAGAAGCCCG	AGTCGTCGTG	CCCGGCGCGG	GTGGTGGCCG	AGCTCTCCTT	CCTGCTCATC	1260
CTCGTCTCGT	CCGTGGTCAT	GTGCATGGAC	ACCATCCCCG	AACTGCAGGT	GCTGGACGCC	1320
GAGGGCAACC	GCGTGGAGCA	CCCGACGCTG	GAGAACGTGG	AGACGGCGTG	CATTGGCTGG	1380
TTCACCCTGG	AGTACCTGCT	GCGCCTCTTC	TCGTACCCCA	ACAAGCTGCA	CTTCGCGCTG	1440
TCCTTCATGA	ACATTGTGGA	CGTGCTGGCC	ATCCTCCCCT	TCTACGTGAG	CCTCACGCTC	1500
ACGCACCTGG	GTGCCCGCAT	GATGGAGCTG	ACCAACGTGC	AGCAGGCCGT	GCAGGCGCTG	1560
CGGATCATGC	GCATCGCGCG	CATCTTCAAG	CTGGCCCCGC	ACTCCTCGGG	CCTGCAGACC	1620
CTCACCTATG	CCCTCAAGCG	CAGCTTCAAG	GAAGTGGGGC	TGCTGCTCAT	GTACCTGGCA	1680
GTGGGTATCT	TCGTCTTCTC	TGCCCTGGGC	TACACCATGG	AGCAGAGCCA	TCCAGAGACC	1740
CTGTTTAAGA	ACATCCCCCA	GTCCTTCTGG	TGGGCCATCA	TCACCATGAC	CACCGTCGGC	1800
TACGGCGACA	TCTACCCCAA	GACCACGCTG	AGCAAGCTCA	ACGCGGCCAT	CAGCTTCTTG	1860
TGTGGTGTCA	TTGCCATCGC	CCTGCCCATC	CACCCCATCA	TCAACAACCT	TGTCAGGTAC	1920
TACAACAAGC	AGCGCGTCCT	GGAGACCGCG	GCCAAGCAGC	AGCTGGAGCT	GATGGAACCTC	1980
AACTCCAGCA	GCGGGGGCGA	GGGCAAGACC	GGGGGCTCCC	GCAGTGACCT	GGACAACCTC	2040
CCTCCAGAGC	CTGCGGGGAA	GGAGGCGCCG	AGCTGCAGCA	GCCGGCTGAA	GCTCTCCAC	2100
AGCGACACCT	TCATCCCCCT	CCTGACCGAG	GAGAAGCACC	ACAGGACCCG	GCTCCAGAGT	2160
TGCAAGTGAC	AGGAGGCCCC	TCAGGCAGAG	ATGGACCAGG	CGGTGGACAG	ATGGGTAGAT	2220
GTGGCAGGCA	TGTCATCGAC	AGCACAGAAG	GGCTGTCCTG	TGTCCCCCA	ACCCTCCCCT	2280
GGACAGACTC	TGAAGGCCCT	CCCGGCACCT	CTGCCAAGGC	TGGGTAAGAC	TCCTCTATGT	2340
TGCCTGCTGT	CCAGGAGCCC	GGGAGGGAGG	GGTGTGCAGG	AGCCGCAGGG	CCGTGTGGGA	2400

CGAGTGGAGG CCGCGGCCTG GCTGGCACGA GAGCCCACGC CCGCTTCTGT ATCTCCCTCA 2460  
 ATAAAGCCTC CTGCTCTGTG CAA 2483

(5) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 494 AMINO ACIDS
- (B) TYPE: AMINO ACID
- (C) STRANDEDNESS:
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Asp	Gly	Ser	Gly	Glu	Arg	Ser	Leu	Pro	Glu	Pro	Gly	Ser	Gln	15
				5					10						
Ser	Ser	Ala	Ala	Ser	Asp	Asp	Ile	Glu	Ile	Val	Val	Asn	Val	Gly	30
				20					25						
Gly	Val	Arg	Gln	Val	Leu	Tyr	Gly	Asp	Leu	Leu	Ser	Gln	Tyr	Pro	45
				35					40						
Glu	Thr	Arg	Leu	Ala	Glu	Leu	Ile	Asn	Cys	Leu	Ala	Gly	Gly	Tyr	60
				50					55						
Asp	Thr	Ile	Phe	Ser	Leu	Cys	Asp	Asp	Tyr	Asp	Pro	Gly	Lys	Arg	75
				65					70						
Glu	Phe	Tyr	Phe	Asp	Arg	Asp	Pro	Asp	Ala	Phe	Lys	Cys	Val	Ile	90
				80					85						
Glu	Val	Tyr	Tyr	Phe	Gly	Glu	Val	His	Met	Lys	Lys	Gly	Ile	Cys	105
				95					100						
Pro	Ile	Cys	Phe	Lys	Asn	Glu	Met	Asp	Phe	Trp	Lys	Val	Asp	Leu	120
				110					115						
Lys	Phe	Leu	Asp	Asp	Cys	Cys	Lys	Ser	His	Leu	Ser	Glu	Lys	Arg	135
				125					130						
Glu	Glu	Leu	Glu	Glu	Ile	Ala	Arg	Arg	Val	Gln	Leu	Ile	Leu	Asp	150
				140					145						
Asp	Leu	Gly	Val	Asp	Ala	Ala	Glu	Gly	Arg	Trp	Arg	Arg	Cys	Gln	

	155	160	165
Lys Cys Val Trp	Lys Phe Leu Glu Lys	Pro Glu Ser Ser Cys Pro	
	170	175	180
Ala Arg Val Val	Ala Glu Leu Ser Phe	Leu Leu Ile Leu Val Ser	
	185	190	195
Ser Val Val Met	Cys Met Asp Thr Ile	Pro Glu Leu Gln Val Leu	
	200	205	210
Asp Ala Glu Gly	Asn Arg Val Glu His	Pro Thr Leu Glu Asn Val	
	215	220	225
Glu Thr Ala Cys	Ile Gly Trp Phe Thr	Leu Glu Tyr Leu Leu Arg	
	230	235	240
Leu Phe Ser Ser	Pro Asn Lys Leu His	Phe Ala Leu Ser Phe Met	
	245	250	255
Asn Ile Val Asp	Val Leu Ala Ile Leu	Pro Phe Tyr Val Ser Leu	
	260	265	270
Thr Leu Thr His	Leu Gly Ala Arg Met	Met Glu Leu Thr Asn Val	
	275	280	285
Gln Gln Ala Val	Gln Ala Leu Arg Ile	Met Arg Ile Ala Arg Ile	
	290	295	300
Phe Lys Leu Ala	Arg His Ser Ser Gly	Leu Gln Thr Leu Thr Tyr	
	305	310	315
Ala Leu Lys Arg	Ser Phe Lys Glu Leu	Gly Leu Leu Leu Met Tyr	
	320	325	330
Leu Ala Val Gly	Ile Phe Val Phe Ser	Ala Leu Gly Tyr Thr Met	
	335	340	345
Glu Gln Ser His	Pro Glu Thr Leu Phe	Lys Asn Ile Pro Gln Ser	
	350	355	360
Phe Trp Trp Ala	Ile Ile Thr Met Thr	Thr Val Gly Tyr Gly Asp	
	365	370	375
Ile Tyr Pro Lys	Thr Thr Leu Ser Lys	Leu Asn Ala Ala Ile Ser	
	380	385	390
Phe Leu Cys Gly	Val Ile Ala Ile Ala	Leu Pro Ile His Pro Ile	
	395	400	405
Ile Asn Asn Phe	Val Arg Tyr Tyr Asn	Lys Gln Arg Val Leu Glu	
	410	415	420

Thr	Ala	Ala	Lys	His	Glu	Leu	Glu	Leu	Met	Glu	Leu	Asn	Ser	Ser	
				425					430						435
Ser	Gly	Gly	Glu	Gly	Lys	Thr	Gly	Gly	Ser	Arg	Ser	Asp	Leu	Asp	
				440					445						450
Asn	Leu	Pro	Pro	Glu	Pro	Ala	Gly	Lys	Glu	Ala	Pro	Ser	Cys	Ser	
				455					460						465
Ser	Arg	Leu	Lys	Leu	Ser	His	Ser	Asp	Thr	Phe	Ile	Pro	Leu	Leu	
				470					475						480
Thr	Glu	Glu	Lys	His	His	Arg	Thr	Arg	Leu	Gln	Ser	Cys	Lys		
				485					490						

WHAT IS CLAIMED IS:

1. An isolated polynucleotide selected from the group consisting of
  - (a) a polynucleotide encoding a K<sup>+</sup> channel 1 polypeptide having the deduced amino acid sequence of Figure 1 or a fragment, analog or derivative of said polypeptide;
  - (b) a polynucleotide encoding a K<sup>+</sup> channel 2 polypeptide having the deduced amino acid sequence of Figure 2 or a fragment, analog or derivative of said polypeptide;
  - (c) a polynucleotide encoding a K<sup>+</sup> channel 1 polypeptide having amino acid sequence encoded by the cDNA contained in ATCC Deposit No. 75700 or a fragment, analog or derivative of said polypeptide; and
  - (d) a polynucleotide encoding a K<sup>+</sup> channel 2 polypeptide having the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. 75830 or a fragment, analog or derivative of said polypeptide.
2. The polynucleotide of Claim 1 wherein the polynucleotide is DNA.
3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA.
4. The polynucleotide of Claim 1 wherein the polynucleotide is genomic DNA.
5. The polynucleotide of Claim 2 wherein said polynucleotide encodes a K<sup>+</sup> channel 1 polypeptide having the deduced amino acid sequence of Figures 1 and 2.
6. The polynucleotide of Claim 2 wherein said polynucleotide encodes a K<sup>+</sup> channel 1 polypeptide encoded by the cDNA of ATCC Deposit No. 75700.



7. The polynucleotide of Claim 2 wherein said polynucleotide encodes a K<sup>+</sup> channel 2 polypeptide having the deduced amino acid sequence of Figure 2.
8. The polynucleotide of Claim 2 having the coding sequence of a K<sup>+</sup> channel 2 polypeptide deposited as ATCC Deposit No. 75830.
9. A vector containing the DNA of Claim 2.
10. A host cell genetically engineered with the vector of Claim 9.
11. A process for producing a polypeptide comprising: expressing from the host cell of Claim 10 the polypeptide encoded by said DNA.
12. A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of Claim 9.
13. An isolated DNA hybridizable to the DNA of Claim 2 and encoding a polypeptide having K<sup>+</sup> channel 1 polypeptide activity.
14. An isolated DNA hybridizable to the DNA of Claim 2 and encoding a polypeptide having K<sup>+</sup> channel 2 polypeptide activity.
15. A polypeptide selected from the group consisting of (i) a K<sup>+</sup> channel 1 polypeptide having the deduced amino acid sequence of Figure 1 and fragments, analogs and derivatives thereof; (ii) a K<sup>+</sup> channel 2 polypeptide having the deduced amino acid sequence of Figure 2 and fragments, analogs and derivatives thereof; (iii) a K<sup>+</sup> channel 1 polypeptide encoded by the cDNA of ATCC Deposit No. 75700 and fragments, analogs and derivatives of said polypeptide; and (iv) a K<sup>+</sup> channel 2 polypeptide encoded by the cDNA of ATCC Deposit No. 75830 and fragments, analogs and derivatives of said polypeptide.

16. The polypeptide of claim 15 wherein the polypeptide is a K<sup>+</sup> channel 1 polypeptide having the deduced amino acid sequence of Figure 1.
17. The polypeptide of claim 15 wherein the polypeptide is a K<sup>+</sup> channel 2 polypeptide having the deduced amino acid sequence of Figure 2.
18. Antibodies against the polypeptide of claim 15.
19. Agonists for the polypeptide of claim 15.
20. Antagonists against the polypeptide of claim 15.
21. A method for the treatment of a patient having need of an agonist to a K<sup>+</sup> channel 1 polypeptide comprising:  
administering to the patient a therapeutically effective amount of the agonist of claim 19.
22. A method for the treatment of a patient having need of an agonist to a K<sup>+</sup> channel 2 polypeptide comprising:  
administering to the patient a therapeutically effective amount of the agonist of claim 19.
23. A method for the treatment of a patient having need to inhibit a K<sup>+</sup> channel 1 polypeptide comprising:  
administering to the patient a therapeutically effective amount of an antagonist/inhibitor of claim 20.
24. A method for the treatment of a patient having need to inhibit a K<sup>+</sup> channel 2 polypeptide comprising:  
administering to the patient a therapeutically effective amount of an antagonist of claim 20.
25. A process for identifying molecules having a modulating effect on K<sup>+</sup> Channel expression which comprises:  
    providing an expression system that produces a functional K<sup>+</sup> channel expression product of a K<sup>+</sup> channel gene;  
    contacting said product with one or more molecules to determine its modulating effect on the bioactivity of said product; and

selecting from said molecules a candidate capable of modulating said  $K^+$  channel expression.

## FIG. 1A

ACAAAGCTGGAGCTCACCGGGTGGCGGCTCTAGAACTAGTGGATCCCCCGGGCTG  
 CAGGGCTCCGAGGGCGGAGCTAGCCGGCCCCCGGACCGAAGTTGGCGGGCTCC  
 GGGAGCAGAGCGGGCTCCCGGGGACTTCCAGGCCCTCTCGGCTCTCGCCCCGGAC  
 CCGTGGGCACTCGGGGGGACGGAAGCCGGCGGGCCCAACTCCGAGGCGGGACGCCG  
 CGACGGAACTGAGGCCCGGAGAGGATGTGAAGGCCCAAAATGACCCCTTACCGGAG  
 M T L L P G D  
 ACAATTCTGACTACGACTACAGCGGCTGAGCTGCACCTCGGACGCCCTCCTCCACCCGG  
 N S D Y D Y S A L S C T S D A S F H P A  
 CCTTCTCCCGCAGCGCCAGGCCATCAAGGGCGGTTCTACCGCGGGCGCAGCGGCTGC  
 F L P Q R Q A I K G A F Y R R A Q R L R  
 GGCCGAGGATGAGCCCCCGCAGGGCTGTACGCCGAGGACCGCCCGTCGGATCATCA  
 P Q D E P R Q G C Q P E D R R R I I I  
 TCAACGTAGCGGCATCAAGTACTCGCTGCCCTGGACCAACGCTGACGAGTCCCGCTGA  
 N V G G I K Y S L P W T T L D E F P L T  
 CGCGCTGGGCCAGCTCAAGGCCCTGCACCAACTTCGACGACATCTCAACGTGTGCGATG  
 R L G Q L K A C T N F D I L N V C D D  
 ACTACGAGCTACCTGCAACGAGTTCTTTCGACCGCAACCGGGGCCCTTCGGCACTA  
 Y D V T C N E F F F D R N P G A F G T I  
 TCCTGACCTTCCTGCGCGGGCAAGCTGCGGCTGCTGCGGAGATGTGCGGCTGTCT  
 L T F L R A G K L R L L R E M C A L S F  
 TCCAGGAGAGCTGCTGTACTGGGGCATCGCGGAGGACCACTGGACGGCTGTGCAAGC  
 Q E E L L Y W G I A E D H L D G C C K R  
 GCCGCTACCTGCAGAAGATTGAGGAGTTCCGGGAGATGGTGAGCGGAGGAAGAGACG  
 R Y L Q K I E E F A E M V E R E E D D  
 ACCGGCTGGACAGCGAGGGCGGACAGCGAGGGCCCCGGCGGAGGGCGGCGCCCTGG  
 A L D S E G R D S E G P A E G E G R L G  
 GCGCTGCATGCGGCGACTGCGCGACATGTGTGAGAGGCGGCACTCGGGGCTGCCTGGCA  
 R C M R R L R D M V E R P H S G L P G K  
 AGGTGTTGCCCTGTGCGGTCTTCTGACCGTCAACCGCGGTCAACCTCTCCGTCA  
 MATCH WITH FIG. 1B

**MATCH WITH FIG. 1A**

V F A C L S V L F V T V T A V N L S V S  
GCACCTTGCCAGCCTGAGGGAGGAGGAGCAGGGCCACTGTTCCCAGATGTGCCACA  
T L P S L R E E E Q G H C S Q M C H N  
ACGTCTTCATCGTGGAGTCGGTGTGCGTGGGCTGGTTCTCCCTGGAGTTCCTCCTGCGGC  
V F I V E S V C V G W F S L E F L L R L  
TCATTACGGCGCCAGCAAGTTCGCCTTCCTGCGGAGCCCGCTGACGCTGATCGACCTGG  
I Q A P S K F A F L R S P L T L I D L V  
TGGCCATCCTGCCCTACTACATACGCTGCTGGTGACGGCGCCGCGCAGGCCGTGCGCA  
A I L P Y Y I T L L V D G A A A G R R K  
AGCCGGCGGGCAACAGCTACCTGGACAAGTGGGGCTGGTGTGCTGCGCTGCTGCGG  
P G A G N S Y L D K V G L V L R V L R A  
CGCTGCGCATCCTGTACGTGATCGCCTGCGCGCCACTCCCTGGGGCTGCAGACGCTGG  
L R I L Y V M R L A R H S L G L Q T L G  
GGCTACGGCGCGCGCTGCACCGCGAGTTCGGGCTCCTGTGCTCTTCTCCTGCGTGG  
L T A R R C T R E F G L L L F L C V A  
CCATCGCCCTCTTCGCGCCCTGCTCTACGTATCATCGAGAACGAGATGCCGACAGCCCCG  
I A L F A P L L Y V I E N E M A D S P E  
AGTTCACAGCATCCCTGCCTGCTACTGGTGGCTGTCTATCACCATGACGACGGTGGACT  
F T S I P A C Y W A V I T M T T V D Y  
ATGGCGACATGGTCCCCAGGAGCACC CGGCCAGGTAGTGGCCCTGAGCAGCATCCTGA  
G D M V P R S T P G Q V V A L S S I L S  
GCGGCATCCTGCTCATGGCCTTCCAGTCACCTCCATCTTCCACACCTTCTCCCCCTCCT  
G I L L M A F P V T S I F H T F S P S Y  
ACCTGGAGCTCAACAGGAGCAAGAGGGTGATGTTCCGGAGGGCGCAGTTCCTCATCA  
L E L K Q E Q E R V M F R R A Q F L I K  
AAACCAAGTCGCAGCTGAGCGTGTCCAGGACAGTGACATCTTGTTCGGAAGTGCCTCCT  
T K S Q L S V S Q D S D I L F G S A S S  
CGGACACCAGAGACAATACTAGCGCGGAGGACACGCCCTGCCCTGCCATCTGTGG  
D T R D N N \*

**MATCH WITH FIG. 1C**

## FIG. 1C

MATCH WITH FIG. 1B

CCCGAAGCCATTGCCATCCACTGCAGACGCCCTGGAGAGGGACAGCGCTTCCGAGTGCA  
 GTCTGGCGCAGCACCGACTCCACGCACCCGGGAAGGACACCTCACTCCACACCCC  
 GGAAGAACACTAGAACATCAGCAGAGGGCCCTGCCCTCCGCTGACGCCGTGAAGG  
 AAGCTGGGTCAATCAGCCAGCCCGCCACCCAGCCCTATGTGTGTTTCCCTCAATAA  
 GGAGATGCCCTTGTCTTTTCAACCATGC

## FIG. 2A

10 GGTCGCAACCCCTCGGTGACCCGCTGCGCCCGAGGAGGGCGGTGCGGGTGGTGG 50  
 70 CGCGGGCGCGCAGCTGTGCCCCGTCTGCCCAAGGGTTAATCCGTCCCTGCAGCTGCCG 110  
 130 CGCGTGCCCTTGCAAGAAATTCACCAGAAAGAGGGTACAGTTTGAAAAGCTCCTGACGTCAGG 170  
 190 CTGGAAATTCCTATTGTGTTAGAAAAGGCTCGGGCAAGCCAGCCCCAAGTTCGCTCTCTG 230  
 250 CACACCTCGAGCACCTCGCGGACGGGTGGTCCGCCAGCTCCGGGACCTGCCGCCGCTG 290  
 310 CCTGCGCGCCCCGGCGGAGGACGGTGCCAGCCGCCACGAGGAGACCCGCTCCCGCA 350  
 370 GGAGCGCGAGCTGAAGCGGGGAGCGCGCCAGCCAGCCGGGTGAGTGCCCCGGGCG 410  
 430 AGGCGGCGCGGCCCAAGCCCCCGGGGTTCGTCCGGGCGCCGGATGCCAGCCCCGAG 470  
 490 CCCC GCCCGGTGCATGCCTCCCCCGCGGCGGCCCGGAGGCTGCTGCCCGCTGTG 530  
 550 MATCH WITH FIG. 2B 570 590

## FIG. 2B

MATCH WITH FIG. 2A

ACCGCCCTTCCCCGAGGGCGGGCGGCGAGGCTCTCCACGAGATACGACGCACGGGT  
 610 630 650  
 GGCACCCCGGACCCCAACGACAACGGCGGGCGGACGTCTGCAGGGGGCGGGCGGGAG  
 670 690 710  
 CCTGCGAGGGCGGCACGGGGAGGATGGACGGGTCCGGGGAGCGCAGCCTCCCGGAGCCG  
 730 750 770  
 M D G S G E R S L P E P  
 GGCAGCCAGAGCTCCGCTGCCAGCGACACATAGAGATAGTCGTCAACGTGGGGGGCGTG  
 790 810 830  
 G S Q S S A A S D D I E I V V N V G G V  
 CGGCAGGTGCTGTACGGGACCTCCTCAGTCAGTACCTGAGACCCGGCTGGCGGAGCTC  
 850 870 890  
 R Q V L Y G D L L S Q Y P E T R L A E L  
 ATCAACTGCTTGGCTGGGGCTACGACACCATCTTCTCCCTGTGCGACGACTACGACCCC  
 910 930 950  
 I N C L A G G Y D T I F S L C D D Y D P  
 GGCAAGCGCGAGTTCTACTTTGACAGGGACCCGGACGCCCTTCAAGTGTGTCTCGAGGTG  
 970 990 1010  
 G K R E F Y F D R D P D A F K C V I E V  
 TACTATTTCGGGAGGTCCACATGAAGAAGGGCATCTGCCCCCATCTGCTTCAAGAACGAG  
 1030 1050 1070  
 Y Y F G E V H M K K G I C P I C F K N E  
 ATGGACTTCTGGGAAGGTGGACCTCAAGTTCTCTGGACGACTGTTGCAAGAGCCACCTGAGC  
 1090 1110 1130  
 M D F W K V D L K F L D D C C K S H L S  
 GAGAAGCGCGAGGAGCTGGAGGAGATCGCGCGCGCGGTGCAGCTCATCctgGACGACCTG

MATCH WITH FIG. 2C

## FIG. 2C

MATCH WITH FIG. 2B

E K R E E L E E I A R R V Q L I L D D L  
1150 1170 1190  
GGGTGGACGGCCGAGGGCCGCTGGCGCCGCTGCCAGATGTGCGTCTGGAAGTTCCTG  
G V D A A E G R W R R C Q K C V W K F L  
1210 1230 1250  
GAGAAGCCCGAGTCGTCGTCGCCGCGGGTGGTGCCGAGCTCTCCTTCTGCTCATC  
E K P E S S C P A R V V A E L S F L L I  
1270 1290 1310  
CTCGTCTCGTCCGTGGTCATGTGCATGGACACCATCCCCGAACGTGCAGGTGCTGACGCC  
L V S S V V M C M D T I P E L Q V L D A  
1330 1350 1370  
GAGGGCAACCGGTGGAGCACCCGACGCTGGAGAACGTGGAGACGGCGTGCATTGGCTGG  
E G N R V E H P T L E N V E T A C I G W  
1390 1410 1430  
TTCACCTGGAGTACCTGCTGGCGCCTCTTCTCGTCACCCAAAGCTGCACCTTCGGCGTG  
F T L E Y L L R L F S S P N K L H F A L  
1450 1470 1490  
TCCTTCATGAACATTGTGGACGTGCTGGCCATCTCTCCCTTCTACGTGAGCTCTACGCTC  
S F M N I V V V L A I L P F Y V S L T L  
1510 1530 1550  
ACGCACCTGGGTGCCCGCATGATGGAGCTGACCAACGTGCAGCAGGCCGTGCAGGCGCTG  
T H L G A R M M E L T N V Q Q A V Q A L  
1570 1590 1610  
CGGATCATGGCGCATCGCGCATCTTCAAGCTGGCCCGCCACTCTCGGCGCTGCAGACC  
R I M R I A R I F K L A R H S S G L Q L  
1630 1650 1670

MATCH WITH FIG. 2D



## FIG. 2D

MATCH WITH FIG. 2C

CTCACCTATGCCCTCAAGCGCAGCTTCAAGAACTGGGGCTGCTGCTCATGTACCTGGCA  
 L T Y A L K R S F K E L G L L L M Y L A  
 1690 1710 1730  
 GTGGGTATCTTCGTCTTCTCTGCTGCCCTGGGCTACACCATGGAGCAGAGCCATCCAGAGACC  
 V G I F V F S A L G Y T M E Q S H P E T  
 1750 1770 1790  
 CTGTTTAAACAATCCCCAGTCCTTCTGTGGGCCATCATCACCATGACCACTCGGC  
 L F K N I P Q S F W W A I I T M T V G  
 1810 1830 1850  
 TACGGCGACATCTACCCCAAGACCGCTGAGCAAGCTCAACCGGCCATCAGCTTCTTG  
 Y G D I Y P K T T L S K L N A A I S F L  
 1870 1890 1910  
 TGTGTGTCAATTGCCATCGCCCTGCCCATCCACCCCATCATCAACAACCTTGTGAGGTAC  
 C G V I A I A L P I H P I I N N F V R Y  
 1930 1950 1970  
 TACAACAAGCAGCGCTCTGGAGACCGCGGCCAAGCAGAGCTGGAGCTGATGGAACTC  
 Y N K Q R V L E T A A K H E L E L M E L  
 1990 2010 2030  
 AACTCCAGCAGCGGGGCGAGGGCAAGACCGGGGGCTCCCGCAGTGACCTGGACAACCTC  
 N S S S G G E G K T G G S R S D L D N L  
 2050 2070 2090  
 CCTCCAGAGCCTGCGGGAAGGAGCGCGCGAGCTGCAGCAGCCGGCTGAAGCTCTCCAC  
 P P E P A G K E A P S C S S R L K L S H  
 2110 2130 2150  
 AGGACACCTTCATCCCCCTCCTGACCGAGGAGAAGCACCACAGGACCCGGCTCCAGAGT  
 S D T F I P L L T E E K H H R T R L Q S

MATCH WITH FIG. 2E

## FIG. 2E

MATCH WITH FIG. 2D

2170	2190	2210
TTGCAAGTGACAGGAGGCCCTCAGGCAGAGATGGACCGGTGGACAGATGGGTAGAT		
C K *		
2230	2250	2270
GTGGCAGGCATGTCAATCGACAGCACAGAAAGGCTGTCTCTGTCCCTCCCAACCCCTCCCT		
2290	2310	2330
GGACAGACTCTGAAGGCCTCTCCGGCACCTTCGCCCAAGGCTGGGTAAGACTCCTCTATGT		
2350	2370	2390
TGCCTGCTGTCCAGGAGCCCGGAGGGAGGGGTGTGCAGGCGCAGGGCGGTGTGGGA		
2410	2430	2450
CGAGTGGAGGCCCGGCCTGGCTGGCACGAGAGCCCAAGCCCGCTTCTGTATCTCCCTCA		
2470		
ATAAAGCCCTCCTGCTCTGTGCAA		

FIG. 3A

[illegible]

MATCH WITH FIG. 3A

FIG. 3B

100 RTGR LHMMEEMCALSF SQELDYWGIDEIYLESCCQARYHQKKEQMNEELK 149

141 RVQLIL...DDLGVDAAEGRWRRRCQKCVCWKFLKPESSCPARVVAELS 188

150 REAETLREREGEFFDNTCCAERKK...LWDLLEKPNSSVAAKILAIIS 195

189 FLLILVSSVVMCMDTIP ELQVLDAEGNRVEHPTLENVETACIGWFTLEYL 238

196 IMFIVLSTIALSINTLP ELQSLDEFQGSTDNPQLAHVEAVCIAWFTMEYL 245

239 LRLFSSPNKLHFALSF MNIVDVLAILPFYVSLTLTHLGARMMELTNVQQA 288

246 LRLFSSPKKWKFFKGPLNAIDLAILPYVVTIFLTESNKSVLQFQNVRRV 295

289 VQALRIMRIARIFKLARHSSGLQTLTYALKRSFKELGLLLMYLAVGIFIF 338

296 VQIFRIMRIILRLKLARHSTGLQSLGFTLRRSYNELGLLLFLAMGIMIF 345

339 SALGYTMEQSHPETL FKNIPQSFWWAITMTTVGYGDIYPKTTLSKLNAA 388

MATCH WITH FIG. 3C

9 / 9

MATCH WITH FIG. 3B

## FIG. 3C

346	SSLVFFAEKDEDDTKFKSIPASFWWATITMTTVGYGDIYPKTLGKIVGG	395
389	ISFLCGVIAIALPIINNFVRYNQRVLETAAK	424
396	LCCIAGVLVIALPIPIIVNNFSEFYKEQKRQEKAIKRREALERAKRNGSI	445
425	HELELMELNSSSGGEGKGTGGSRSDDLNLPP	454
446	VSMNMKDAFARSIEMMDIVVEKNGENMGKKDKVQDNHLSPNKWKWKRTL	495
455	EPAGKEAPSCSSRLKLSHSDTFIPLLTEEKHHRTRLQ	491
496	SETSSSKSFETKEQGSPEKARSSSPQHLN	540
492	S	492
541	S	541

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/08449

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : 435/69.1, 240.1, 252.3, 254, 320.1; 530/350; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 240.1, 252.3, 254, 320.1; 530/350; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Proceedings of the National Academy of Sciences USA, Volume 91, issued April 1994, R. Milkman, "An <i>Escherichia coli</i> homologue of eukaryotic potassium channel proteins", pages 3510-3514, entire document.	1-17
A	Annals of the New York Academy of Sciences, Volume 707, issued 1993, M. Li et al., "Assembly of potassium channels", pages 51-59, entire document.	1-17
X	Journal of Neuroscience, Volume 12, Number 2, issued February 1992, J.A. Drewe et al., "Distinct spatial and temporal expression patterns of K <sup>+</sup> channel mRNAs from different subfamilies", pages 538-548, entire document.	1-17

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

•	Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
'A'	document defining the general state of the art which is not considered to be of particular relevance	'X'	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
'E'	earlier document published on or after the international filing date	'Y'	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
'L'	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	'A'	document member of the same patent family
'O'	document referring to an oral disclosure, use, exhibition or other means		
'P'	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

15 NOVEMBER 1994

Date of mailing of the international search report

05 DEC 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GABRIELE BUGAJSKY

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/08449

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 19-25  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
Please See Extra Sheet.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-17

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/08449

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07H 21/00, 21/04; C07K 14/435, 16/18; C12N 1/19, 1/21, 5/10, 15/12, 15/63; C12P 21/02

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, Dialog files 5, 155, 357 (Biosis, Medline, Biotechnology Abstracts), N-Geneseq 16; EMBL-New 9, Genbank 84, Genbank-New 9, UEMBL 39 84, A-Geneseq 16, PIR 41, Swiss-Prot 29  
search terms: potassium, channel?, shab, shaker, shaw, shal, drk?, delay? (3n) rectif?, brain, gene? ?, DNA, human,

## BOX I. OBSERVATIONS WHERE CLAIMS WERE FOUND UNSEARCHABLE

2. Where no meaningful search could be carried out, specifically:

No agonists, antagonists or treatment methods have been provided for; the specification merely discloses the potential for any of the above. It is not even clear that the disclosed genes encode bona fide K<sup>+</sup> channels, as the only evidence supporting such a conclusion is based on sequence similarities; no functional analyses of the translation product have been performed to demonstrate channel activity. Without a showing of the biological role of the translated product, it is impossible to search for agonists, antagonists, etc.

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim(s) 1-17, drawn to K<sup>+</sup> channel genes; cloned cells, expression method, and expressed protein.

Group II, claim(s) 18, drawn to antibodies directed against channel proteins.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: An antibody is encoded by an entirely different DNA than that the protein which is bound by it, and the primary sequence of the antibody bears no relationship to the sequence of the detected protein.

